%20BIANCO.png)
About us
Lever Bio was launched by Claris Ventures and Exor Ventures, with the aim to collaborate with top researchers to drive innovative drug development programs.
The Company was incorporated in 2024 and in the first-half 2025 closed the in-licensing and kicked-off the development of 6 programs in the therapeutic area of immuno-oncology.
Our vision is to unlock biotech innovation in immuno-oncology working with researchers, universities and research centers to ultimately improve patient outcomes.
Our mission
Our mission is to advance promising immuno-oncology drug development programs from discovery to preclinical and clinical stages. Lever Bio aims to translate groundbreaking discoveries in immuno-oncology into next-generation cancer immunotherapies.
Board of Directors
Chief Executive Officer
Pietro Puglisi
Pietro Puglisi is Managing Partner of Claris Ventures, with a background in biomedical engineering and an MBA from Collège des Ingénieurs
Board Member
Noam Ohana
Noam Ohana is Managing Partner of Ora Global and Independent Managing Partner at Exor Ventures.
Our Team
Project Manager
Chiara Donini
Chiara Donini is a researcher specialised in immuno-oncology, immunotherapy and cell therapy.
Investors
In-licensing opportunities
Operating in partnership with top universities and research centers, Lever Bio is open to in-licensing opportunities of immuno-oncology assets originating from Italian research centers or Italian researchers based outside Italy.
Join Lever Bio in advancing promising research and driving innovative drug development in the immuno-oncology field